65,437 trials
Cognitive Change · Health Behavior · Health Literacy
Primary: Leisure Activities Questionnaire Activities Sum — 1.45; 4.45; 11.25 score on a scale — p=<0.05
Dry Eye
Primary: Tear Osmolarity — 13.4; 11.8 mOsm/L
Sarcoma · Sarcoma Metastatic
Primary: Overall Response Rate — 0; 2 Participants
Chronic Pain · Traumatic Brain Injury · Posttraumatic Stress Disorder
Primary: Change in Oswestry Disability Index (ODI) — 48.6; 45.1; 38.3; 47.8 score on a scale — p=.001
Type 2 Diabetes
Primary: Mean Change in HbA1C ≤ 7.5% — -0.5; 0 % glycated hemoglobin — p=0.009
Degenerative Meniscal Tear
Primary: KOOS4 - Change From Baseline — 24.4; 25.3 units on a scale — p=<0.05
Hearing Aids
Primary: Real Ear Measures — 61.23; 60.23; 60.5; 64.53 dB SPL — p=<0.05
Overactive Bladder · Urinary Tract Infection
Primary: Number of Participants With Elevated Cytokines (Levels of Pro-inflammatory) — 20; 20; 16 Participants
Chronic Hepatitis Delta
Primary: Percentage of Participants With Sustained Virological Response at Week 24 After the Scheduled End of Treatment (SVR24) — 16.7; 32.0; 46.0; 12.0 percentage of…
Hormone Receptor Positive Malignant Neoplasm of Breast · Human Epidermal Growth Factor 2 Negative Carcinoma of Breast · Estrogen Receptor Positive Breast Cancer
Primary: Progression Free Survival (PFS) Per RECIST 1.1 — 9.13 Months
Kidney Failure, Chronic
Primary: Kidney Disease Quality — 75.4; 78.3; 78.4; 73.4 score on a scale
Prostate Cancer · Erectile Dysfunction
Primary: Number of Participants Recruited — 12; 0 Participants
Healthy
Primary: Change in Added Sugar Intake Among Children — 11.7; 19.1 g/day — p=0.17
Parkinson Disease · Dysphagia
Primary: Change in Time-to-laryngeal-vestibule-closure Thin Liquids — 0 milliseconds
Aging · Sarcopenia
Primary: Maximal Knee Extensor Velocity — 10.83; 11.91; 11.24 rad/s — p=0.0833